Knowledge Research Center — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$267,401	70
2024	Research	$746,333	148
2023	Research	$541,024	39

Breakdown

Who paid Research payments · program years 2023–2025

Genentech, Inc. $784,611 54 payments
CapsoVision, Inc. $479,490 16 payments
Bausch Health US, LLC $158,794 142 payments
Madrigal Pharmaceuticals $87,642 22 payments
Regeneron Pharmaceuticals, Inc. $22,215 6 payments
Boehringer Ingelheim International GmbH $22,007 17 payments

Studies the money was for Research payments · program years 2023–2025

Roche Cancer Screening Collection Study $784,611 54 payments
Cln-Cvi-5794 $479,490 16 payments
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) $158,794 142 payments
A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) $87,642 22 payments
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors $22,215 6 payments
Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial $22,007 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.